Optionale Produktanalyse
Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
Ulta Beauty Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $23.3B | |
|---|---|---|
| Revenue (ttm) | 13B | |
| Net income (ttm) | 1.2B | |
| EPS (ttm) | $27.4 | |
| Shares out | 42.8M | |
| P/E (trailing) | 22.5x | |
| P/E (forward) | 19.6x | |
| Volume | 348,647 | |
| Beta | 0.84 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-29 | 2023-01-28 | 2024-02-03 | 2025-02-01 | 2026-01-31 | Trend |
| Revenue | $8.63B | $10.21B | $11.21B | $11.30B | $12.39B | +9.5% |
| Gross profit | $3.37B | $4.04B | $4.38B | $4.39B | $4.85B | +9.5% |
| Operating income | $1.30B | $1.64B | $1.68B | $1.56B | $1.53B | +4.3% |
| Net income | $985.8M | $1.24B | $1.29B | $1.20B | $1.15B | +4.0% |
| EPS (diluted) | $17.98 | $24.01 | $26.03 | $25.34 | $25.64 | +9.3% |
| EBITDA | $1.57B | $1.88B | $1.94B | $1.85B | $1.83B | +4.0% |
| R&D | $926.0K | $1.0M | $889.0K | $306.0K | — | -30.9% |
| SG&A | $2.06B | $2.40B | $2.69B | $2.81B | $3.30B | +12.5% |
Recent company headlines from major financial publishers.
Net sales compound moderately and operating margins remain stable. Store-fulfilled digital orders leverage retail fixed overhead, counterbalanced by persistent promotional activity. Substantial free cash flow generation and disciplined share repurchases support steady per-share compounding through FY2028.
Prestige beauty product innovation, category expansion into wellness routines, and store-fulfilled digital efficiencies drive accelerating comparable store sales growth and operating margin expansion, supporting robust earnings compounding alongside authorized capital return programs.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.2% | $520 | $532 | $544 | $558 | $573 |
| 8.7% | $493 | $502 | $513 | $524 | $536 |
| 9.2% | $470 | $477 | $486 | $495 | $505 |
| 9.7% | $449 | $456 | $463 | $470 | $479 |
| 10.2% | $431 | $437 | $443 | $449 | $456 |
Upcoming earnings date and setup when available.
Das Rating, das die veröffentlichte Research-Ausgabe des jeweiligen Monats trug. Ein Rating vergleicht den Kurs zum Analysezeitpunkt mit dem Fair Value; es ist kein Nachweis, ob die Einschätzung zutraf.
| Jahr | Jan | Feb | Mär | Apr | Mai | Jun | Jul | Aug | Sep | Okt | Nov | Dez |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |